BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
October 31 2023 - 7:00AM
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical
company utilizing artificial intelligence to develop transformative
medicines in neuroscience, today announced that it will release its
third quarter 2023 financial results on Tuesday, November 14, 2023
before the open of the U.S. financial markets. BioXcel
Therapeutics’ management team will also host a conference call and
webcast at 8:00 AM ET that day to discuss the Company’s financial
results and to provide a general business update.
Conference
Call & Webcast Details |
|
|
Date/Time: |
Tuesday, November 14, 2023, at
8:00 AM Eastern Time |
Domestic: |
877-407-5795 |
International: |
201-689-8722 |
The webcast link will be accessible under "News/Events" on the
Investors & Media page of the Company's website
at www.bioxceltherapeutics.com.
Replay* |
|
Domestic: |
877-660-6853 |
International: |
201-612-7415 |
Conference
ID: |
13742187 |
*Replay available through February 14, 2024
About BioXcel Therapeutics, Inc.BioXcel
Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company
utilizing artificial intelligence to develop transformative
medicines in neuroscience. The Company’s drug re-innovation
approach leverages existing approved drugs and/or clinically
validated product candidates together with big data and proprietary
machine learning algorithms to identify new therapeutic
indications. For more information, please
visit bioxceltherapeutics.com.
Forward-Looking Statements.This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements
contained in this press release other than statements of historical
fact should be considered forward-looking statements, including,
without limitation, the date and time of the Company’s third
quarter 2023 financial results call. When used herein, words
including “anticipate,” “believe,” “can,” “continue,” “could,”
“designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements use these words or
expressions. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon the
Company’s current expectations and various assumptions. The Company
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. The Company may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
important factors, including, without limitation, the important
factors discussed under the caption “Risk Factors” in its Quarterly
Report on Form 10-Q for the quarterly period ended June 30, 2023,
as such factors may be updated from time to time in its other
filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
except as required by law, it disclaims any obligation to do so,
even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this press release.
Contact Information
Corporate
BioXcel TherapeuticsErik
Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel TherapeuticsBrennan
Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media
Russo PartnersDavid
Schull1.858-717-2310David.schull@russopartnersllc.comScott
Stachowiak1.646-942-5630Scott.stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
BT BIOXCEL THERAPEUTICS is a registered trademark of BioXcel
Therapeutics, Inc. All other trademarks are the properties of their
respective owners.Copyright © 2023, BioXcel Therapeutics, Inc. All
rights reserved.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2024 to May 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From May 2023 to May 2024